biotech / news / / Wallstreet Online
Nxera to receive US$22.5 million in milestone payments from Neurocrine.
Neurocrine has initiated a Phase 2 clinical trial of NBI-1117570 in adults with schizophrenia.
KEY POINTS
- Nxera will receive US$22.5 million in milestone payments from Neurocrine, to be recognized in Q1 FY2026.
- NBI-1117570 is the second NxWave-discovered muscarinic agonist to advance to Phase 2 trials with Neurocrine.
- The Phase 2 trial will assess NBI-1117570's efficacy and safety in approximately 120 hospitalized schizophrenia patients.
COMPANIES
Summarized by Newsio from Wallstreet Online. How we summarize →